Search 

Quintiles is the only fully integrated biopharmaceutical services provider offering clinical, commercial consulting and capital solutions worldwide.  We help customers manage change, navigate risk and seize opportunities.  Quintiles has helped develop or commercialize all of the top 50 best-selling drugs.  Our more than 24,000 employees in nearly 60 countries deliver on promises to customers with an unwavering commitment to patients, safety and ethics.

Relay brings you BD Live! – a software solution providing business intelligence to life science professionals to validate opportunities, discover new assets, and assess their pipelines against their competitors. BD Live! provides real-time trend monitoring and comparative asset analysis and complements existing evaluation models to help business development professionals hone in on promising new technologies and avoid transactions that have limited potential.

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, oncology, as well as muscle disorders.  Partnering projects include: 1) R763 an Aurora Kinase inhibitor for oncology with Phase 2 results and 2)  R723 a selective Jak2 inhibitor in preclinical development for Thrombocytosis in RA, RA, and Myeloproliferative Diseases (hematology). 

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract).

Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world’s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter's lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.

At Roche we focus on developing medicines and diagnostics that will help patients live longer, better lives.

We strive to address unmet medical needs through excellence in science – from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring.

Roche Partnering is dedicated to finding the best advances in modern medicine that strengthen the R&D portfolio. Together with external partners, Roche aims to bring new medicines to patients as quickly as possible. Partnering is the doorway to every part of the Roche organisation – from scientists to life cycle teams to the highest levels of management.

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company has constructed antibody libraries containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets.